Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the […]
New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]
San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]